Loading interactive chart...
1DInterval:
Date Range
1 min
Advertisement
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
Other OTC - Other OTC Delayed Price. Currency in USD
Follow
At close: 12:26PM EDT
Mountain
Settings
- PR Newswire
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
- South China Morning Post
Fosun Pharma prepares to deliver Da Vinci surgical robots to make advanced medical treatment affordable to Chinese patients
Fosun International, through its Shanghai-based healthcare unit, is ready to deliver its first locally built Da Vinci surgical robots to its clients in a major step to make advanced medical technology affordable to Chinese patients. The first robot has been fully built and completed for an undisclosed client, more than a year after its unit Shanghai Fosun Pharmaceutical Group (Fosun Pharma) joined with California-based Intuitive Surgical to build a 700 million yuan (US$96 million) research and p
- Investing.com
Cevira Phase III trial for non-surgical HSIL treatment meets primary endpoint
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
Advertisement
Advertisement
Advertisement